Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway.
- Author(s)
- Wormald, S; Milla, L; O Connor, L;
- Details
- Publication Year 2013-10-23,Volume 6,Issue #1,Page 43
- Journal Title
- BMC Medical Genomics
- Publication Type
- JOURNAL ARTICLE
- Abstract
- Tumour growth in colorectal cancer and other solid cancers is frequently supported by activating mutations in the epidermal growth factor receptor (EGFR) signaling pathway (Patholog Res Int 2011:932932, 2011). Treatment of metastatic colorectal cancer with targeted anti-EGFR therapeutics such as cetuximab extends survival in only 25% of patients who test wild-type for KRAS, while the majority of patients prove resistant (J Clin Oncol 28(7):1254--1261, 2010).Prediction of cetuximab responsiveness for KRAS wild-type colorectal cancers is currently not well defined, and prognostic biomarkers would help tailor treatment to individual patients. Somatic mutation of the EGFR signalling pathway is a prevalent mechanism of resistance to cetuximab (Nature 486(7404):532--536, 2012). If the human genome harbours variants that influence susceptibility of the EGFR pathway to oncogenic mutation, such variants could also be prognostic for cetuximab responsiveness.
- Publisher
- BioMed Central
- Keywords
- Metastatic Colorectal Cancer ; EGFR signalling pathway somatic mutation
- Research Division(s)
- Systems Biology And Personalised Medicine
- Publisher's Version
- https://doi.org/10.1186/1755-8794-6-43
- Open Access at Publisher's Site
http://www.biomedcentral.com/1755-8794/6/43- Terms of Use/Rights Notice
- © 2013 Wormald et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creation Date: 2013-10-23 12:00:00